Month: October 2014

WHAT`S GOING ON WITH THE TURKISH ORPHAN DRUGS MARKET?

Ankara, Turkey – Many countries and regions have already defined health policies on orphan drugs for rare diseases. Although there is no official definition in Turkey, all orphan drugs are covered by reimbursement, regardless of their market authorization status.

Posted in Announcements, Health Policy Analyses, Value in Health Regional Issues Tagged with: , , , , , , , ,

THE IMPACT OF PRICE REDUCTIONS AND COST-SHARING RATES IN GREECE

Athens, Greece – Public expenditure on pharmaceuticals in Greece is high (compared to other EU countries) and has increased by 73%, from €3 billion in 2005 to €5.2 billion in 2009. Since 2010, cost containment efforts focused on the reduction

Posted in Health Policy Analyses, Value in Health Regional Issues Tagged with: , , ,

ISPOR ADDRESSES NEW CHALLENGES FOR IMPROVING EUROPEAN HEALTH CARE AT ANNUAL EUROPEAN CONGRESS

Princeton, NJ, USA, October 7, 2014 – The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) will hold its 17th Annual European Congress in Amsterdam from November 8-12, 2014. The theme of this year’s congress is: “New Challenges for Improving

Posted in Announcements, ISPOR News & Press Tagged with: , ,

LOW INCOME DECREASES ADHERENCE TO MEDICATIONS

Beer-Sheva, Israel – Researchers from Ben-Gurion University of the Negev and Maccabi Healthcare Services, the second largest HMO in Israel, revealed that cost-related underuse of chronic pharmaceutical therapy is self-reported among approximately 10% of the chronically-ill patients. This phenomenon is strongly

Posted in Health Policy Analyses, Value in Health Regional Issues Tagged with: , , , ,